Drug
Upadacitinib clinical trials
Also written RINVOQ and ABT-494.
- studies test it
- 94
- open now
- 34
- in phase 3
- 43
- first study started
- 2012
Keep track of what changes. Save the upadacitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
94 studies that test it; most in 2026 (17)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 11 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 25
- Phase 3
- 43
- Phase 4
- 18
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 60 · Other 34
AbbVie (55) · Sixth Affiliated Hospital, Sun Yat-sen University (5) · Peking University People's Hospital (3) · University of California, San Francisco (2) · CARE ARTHRITIS LTD. (2) · Berinstein, Jeffrey (2) · Tianjin Medical University (1) · Peking Union Medical College (1)
Often tested with
Tested in the same studies.
Tofacitinib (5) · Dupilumab (4) · Secukinumab (4) · Elsubrutinib (4) · Adalimumab (3) · Baricitinib (3) · Ixekizumab (3) · Ustekinumab (3)
Studies
Open first, then newest update. How each study uses upadacitinib is read from its arms, and is right about nine times in ten.
Testing it · 94
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingPhase 3AbbVieNCT07772492Written as Upadacitinib
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingPhase 3AbbVieNCT06012240Written as Upadacitinib
- A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingPhase 4The University of Texas Health Science Center, HoustonNCT07770646Written as Upadacitinib (JAKi)
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingPhase 3Douglas D. FraserNCT06928272Written as Upadacitinib
- A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisRecruitingPhase 2University of North Carolina, Chapel HillNCT07588568Written as Upadacitinib 30mg Dose
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.RecruitingPhase 2Centre Hospitalier Universitaire de NiceNCT07492251Written as Upadacitinib
- A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingPhase 1AbbVieNCT07843693Written as Upadacitinib
- Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative ColitisNot yet recruitingPhase 4University of California, San FranciscoNCT07502339Written as Upadacitinib
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingPhase 3AbbVieNCT05609630Written as Upadacitinib
- Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating MutationsNot yet recruitingPhase 1/2Lisa SatterNCT07670156Written as Upadacitinib
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingPhase 4Berinstein, JeffreyNCT05867329Written as Upadacitinib Extended Release Oral Tablet
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingPhase 4University Hospital, ToulouseNCT06687551Written as Upadacitinib 15 MG
- Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance DoseNot yet recruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT07700446Written as Upadacitinib
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Upadacitinib
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingPhase 2RenJi HospitalNCT07678645Written as Upadacitinib 15 MG
- Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）RecruitingPhase 4Yongquan ShiNCT07546097Written as Upadacitinib
- TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT07510191Written as Upadacitinib
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Upadacitinib
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingPhase 3TakedaNCT06227910Written as Upadacitinib
- Upadacitinib as a Novel Treatment for Refractory Eyelid DermatitisRecruitingEarly Phase 1Northwestern UniversityNCT06684522Written as Upadacitinib 15 MG
See all 94 studies that test upadacitinib →
Given in every arm · 4 — upadacitinib is usual care beside what is tested
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingPhase 3AbbVieNCT06461897Written as Upadacitinib
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateActive, not recruitingPhase 3AbbVieNCT02629159Written as Upadacitinib
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsCompletedPhase 3AbbVieNCT03086343Written as Upadacitinib
- A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)CompletedPhase 3AbbVieNCT02706951Written as Upadacitinib
Codes
What other systems call upadacitinib · ClinicalTrials.gg INT000588
- MeSH (NLM) C000613732upadacitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4RA0KN46E0UPADACITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2196092Confirmed FDA, Wikidata
- Wikidata Q27074125upadacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152802UpadacitinibOne source FDA
- DrugBank DB15091One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613732 | upadacitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4RA0KN46E0 | UPADACITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2196092 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27074125 | upadacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152802 | Upadacitinib | One source FDA |
| DrugBank | DB15091 | — | One source Wikidata |
Also registered as upadacitinib hemihydrate (UNII NEW4DV02U5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.